reports
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Resul...
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 8 @ 4:30 p.m. ET Domestic:1-833-470-1428International:1-404-975-4839Conference ID:CRNXQ1 Webcast: Participants can use the dial-in numbers above ...
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under...
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 124,950 shares of its common stock and granted an aggregate of 84,725 restricted stock unit (“RSU”) awards to 26 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement ...
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Va...
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment and long-term maintenance therapy of acromegaly, a serious, rare and progressive endoc...
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under...
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 95,675 shares of its common stock to fifteen new non-executive employees and 80,000 to one new executive employee; and granted an aggregate of 40,775 restricted stock unit (“RSU”) awards to sixteen new non-executive employees and 52,000 to one new executive employee; ...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Fi...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key Stakeholder Engagement Efforts Expecting to Initiate Four Late-Stage Trials and Additional Early-Stage Trials from Development Pipeline in 2025 Strong Financial Position with $1.4B Cash with Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: C...
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Of...
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), today announced the appointment of Tobin “Toby” Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. “I am excited to welcome Toby to our senior leadership team during this trans...
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investo...
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), today announced that company management will participate in two upcoming investment bank conferences. The TD Cowen 45th Annual Healthcare Conference is being held in Boston, MA, and the Leerink Global Healthcare Conference is taking place in Miami, FL. TD Cowen 45th Annual Healthcare Conference Fireside chat on Monday, March 3, 2025 at 11:10 a.m. Eastern Time Webcast link Leerink Global Healthcare Conference Firesi...
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Un...
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock and granted an aggregate of 9,950 restricted stock unit (“RSU”) awards to 14 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Induce...
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 ...
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 27 @ 4:30 p.m. ET Domestic: 1-800-267-6316International: 1-203-518-9783Conference ID: CRNXQ4 Webc...
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Und...
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,100 shares of its common stock to sixteen new non-executive employees and 100,000 to one new executive employee under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted...
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atu...
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione Meaningful Improvements Demonstrated in Multiple Clinical Signs and Symptoms of CAH Affecting Patient Health Safety and Efficacy Data Support Initiation of Phase 3 Clinical Trial Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) to...
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morga...
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 14, 2025 at 4:30 p.m. Pacific Time. To access the live webcast, . The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at . If you are interest...
Molecular Templates Announces Notice of Delisting and Failure to Satis...
Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the “Staff”) of The Nasda...
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercia...
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company’s commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the company’s deep, innovative pipeline of candidates. “Isabel is a highly acc...
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Un...
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on December 10, 2024, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock to sixteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employe...
Crinetics Announces FDA Acceptance of New Drug Application for Paltuso...
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025 SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for investigational candidate paltusotine for the treatment and long-term maintenance therapy of acromegaly in adults. If approved, paltusotine will be the first and only once-daily, oral, selective somatostatin receptor type 2 nonpepti...
Molecular Templates Announces Receipt of Expected Notification of Defi...
Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announc...
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements wi...
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025 Data From Phase 2 Trial of Paltusotine in Carcinoid Syndrome to be Highlighted in Crinetics Symposium and Two Presentations SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced two abstracts f...
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuro...
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025 Data From Phase 2 Trial of Paltusotine in Carcinoid Syndrome to be Highlighted in Crinetics Symposium and Two Presentations SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced two abstracts from its t...
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results...
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of $575M of Common Stock Debut of First Drug Candidate from a Novel Nonpeptide Drug Conjugate Platform at North American Neuroendocrine Tumor Society (NANETS) Total of Four New Drug Candidates in IND-Enabling Preclinical Studies Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: C...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.